Hypoxia-associated protein expression in primary central nervous system diffuse large B-cell lymphoma: does it predict prognosis?

References

• Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000;88: 1474–1480.
   PubMed Web of Science ®Google Scholar
• Semenza GL. Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol 2009;19:12–16.
   PubMed Web of Science ®Google Scholar
• Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266–276.
   PubMed Web of Science ®Google Scholar
• Harris AL. Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38–47.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Rabbani ZN, Dewhirst MW, et al. Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 2005;49:325–335.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Shin HJ, Jung KY, et al. Prognostic value of carbonic anhydrase IX and Ki-67 expression in squamous cell carcinoma of the tongue. Jpn J Clin Oncol 2007;37:812–819.
   PubMed Web of Science ®Google Scholar
• Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509–4515.
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;53:1192–1202.
   PubMed Web of Science ®Google Scholar
• Stewart M, Talks K, Leek R, et al. Expression of angiogenic factors and hypoxia inducible factors HIF 1, HIF 2 and CA IX in non-Hodgkin's lymphoma. Histopathology 2002;40:253–260.
   PubMed Web of Science ®Google Scholar
• Passam FH, Alexandrakis MG, Kafousi M, et al. Histological expression of angiogenic factors: VEGF, PDGFRalpha, and HIF-1alpha in Hodgkin lymphoma. Pathol Res Pract 2009;205:11–20.
   PubMed Web of Science ®Google Scholar
• Giatromanolaki A, Koukourakis MI, Pezzella F, et al. Phosphorylated VEGFR2/KDR receptors are widely expressed in B-cell non-Hodgkin's lymphomas and correlate with hypoxia inducible factor activation. Hematol Oncol 2008;26:219–224.
   PubMed Web of Science ®Google Scholar
• Evens AM, Sehn LH, Farinha P, et al. Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2010;28:1017–1024.
   PubMed Web of Science ®Google Scholar
• Silver I, Erecinska M. Oxygen and ion concentrations in normoxic and hypoxic brain cells. Adv Exp Med Biol 1998;454:7–16.
   PubMed Web of Science ®Google Scholar
• Uhm JE, Kim KH, Yi SY, et al. A retrospective study to compare two methotrexate-based regimens for primary central nervous system lymphoma. Leuk Lymphoma 2009;50:1110–1118.
   PubMed Web of Science ®Google Scholar
• Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005;23:5034–5043.
   PubMed Web of Science ®Google Scholar
• Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996;17:343–346.
   PubMedGoogle Scholar
• Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721–732.
   PubMed Web of Science ®Google Scholar
• Kallio PJ, Wilson WJ, O'Brien S, Makino Y, Poellinger L. Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J Biol Chem 1999;274:6519–6525.
   PubMed Web of Science ®Google Scholar
• Haugland HK, Vukovic V, Pintilie M, et al. Expression of hypoxia-inducible factor-1alpha in cervical carcinomas: correlation with tumor oxygenation. Int J Radiat Oncol Biol Phys 2002;53:854–861.
   PubMed Web of Science ®Google Scholar
• Mineta H, Miura K, Ogino T, et al. Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas. Br J Cancer 2000;83:775–781.
   PubMed Web of Science ®Google Scholar
• Rasheed S, Harris AL, Tekkis PP, et al. Hypoxia-inducible factor-1alpha and -2alpha are expressed in most rectal cancers but only hypoxia-inducible factor-1alpha is associated with prognosis. Br J Cancer 2009;100:1666–1673.
   PubMed Web of Science ®Google Scholar
• Sulkowska M, Wincewicz A, Sulkowski S, Koda M, Kanczuga-Koda L. Relations of TGF-beta1 with HIF-1 alpha, GLUT-1 and longer survival of colorectal cancer patients. Pathology 2009;41:254–260.
   PubMed Web of Science ®Google Scholar
• Kawamura T, Kusakabe T, Sugino T, et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer 2001;92:634–641.
   PubMed Web of Science ®Google Scholar
• Oliver RJ, Woodwards RT, Sloan P, Thakker NS, Stratford IJ, Airley RE. Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection; results of EORTC Translational Research Fund studies. Eur J Cancer 2004;40:503–507.
   PubMed Web of Science ®Google Scholar
• Shim HK, Lee WW, Park SY, Kim H, So Y, Kim SE. Expressions of glucose transporter types 1 and 3 and hexokinase-II in diffuse large B-cell lymphoma and other B-cell non-Hodgkin's lymphomas. Nucl Med Biol 2009;36:191–197.
   PubMed Web of Science ®Google Scholar
• Shim HK, Lee WW, Park SY, Kim H, Kim SE. Relationship between FDG uptake and expressions of glucose transporter type 1, type 3, and hexokinase-II in Reed-Sternberg cells of Hodgkin lymphoma. Oncol Res 2009;17:331–337.
   PubMed Web of Science ®Google Scholar
• Khandani AH, Dunphy CH, Meteesatien P, Dufault DL, Ivanovic M, Shea TC. Glut1 and Glut3 expression in lymphoma and their association with tumor intensity on 18F-fluorodeoxyglucose positron emission tomography. Nucl Med Commun 2009;30:594–601.
   PubMed Web of Science ®Google Scholar
• Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999;59:728–733.
   PubMed Web of Science ®Google Scholar
• Foekens JA, Peters HA, Grebenchtchikov N, et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001;61:5407–514.
   PubMed Web of Science ®Google Scholar
• Gratzinger D, Zhao S, Tibshirani RJ, et al. Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Lab Invest 2008;88:38–47.
   PubMed Web of Science ®Google Scholar